PT3341368T - Novos análogos de nucleósidos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5 - Google Patents

Novos análogos de nucleósidos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5

Info

Publication number: PT3341368T
Authority: PT; Portugal
Prior art keywords: novel; aromatic ring; ring substituted; bicyclic aromatic; nucleoside analogues
Prior art date: 2015-09-07

Application number

PT167572338T

Other languages

English (en)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-07

Filing date

2016-08-25

Publication date

2021-12-09

2016-08-25 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2021-12-09 Publication of PT3341368T publication Critical patent/PT3341368T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Obesity (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PT167572338T 2015-09-07 2016-08-25 Novos análogos de nucleósidos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5 PT3341368T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP15184011		2015-09-07

Publications (1)

Publication Number	Publication Date
PT3341368T true PT3341368T (pt)	2021-12-09

Family

ID=54065259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT167572338T PT3341368T (pt)	2015-09-07	2016-08-25	Novos análogos de nucleósidos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5

Country Status (35)

Country	Link
US (4)	US10653711B2 (pt)
EP (3)	EP3974428A1 (pt)
JP (3)	JP6917978B2 (pt)
KR (1)	KR102716092B1 (pt)
CN (2)	CN107922413B (pt)
AR (1)	AR105820A1 (pt)
AU (4)	AU2016311295B2 (pt)
BR (2)	BR112018003595B1 (pt)
CA (1)	CA2992688A1 (pt)
CL (1)	CL2018000510A1 (pt)
CO (1)	CO2018002063A2 (pt)
CY (1)	CY1125359T1 (pt)
DK (1)	DK3341368T3 (pt)
EA (1)	EA201890573A1 (pt)
ES (1)	ES2901972T3 (pt)
HR (1)	HRP20211997T1 (pt)
HU (1)	HUE057312T2 (pt)
IL (3)	IL311843A (pt)
LT (1)	LT3341368T (pt)
MA (1)	MA42678B1 (pt)
MD (1)	MD3341368T2 (pt)
MX (2)	MX392554B (pt)
MY (1)	MY198472A (pt)
NZ (2)	NZ740528A (pt)
PE (2)	PE20221629A1 (pt)
PH (2)	PH12018500425B1 (pt)
PL (1)	PL3341368T3 (pt)
PT (1)	PT3341368T (pt)
RS (1)	RS62698B1 (pt)
SG (1)	SG10202003775VA (pt)
SI (1)	SI3341368T1 (pt)
SM (1)	SMT202100725T1 (pt)
TN (1)	TN2018000043A1 (pt)
TW (3)	TWI791251B (pt)
WO (1)	WO2017032840A1 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI791251B (zh) *	2015-08-26	2023-02-01	比利時商健生藥品公司	使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
MX374813B (es) *	2016-03-10	2025-03-06	Janssen Pharmaceutica Nv	Análogos de nucleósidos sustituidos para su uso como inhibidores de prmt5.
CA2969295A1 (en)	2016-06-06	2017-12-06	Pfizer Inc.	Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
CN109715634B (zh)	2016-09-14	2022-09-27	詹森药业有限公司	Menin-mll相互作用的稠合二环抑制剂
US12084462B2 (en)	2016-09-14	2024-09-10	Janssen Pharmaceutica Nv	Spiro bicyclic inhibitors of menin-MLL interaction
HUE053907T2 (hu)	2016-09-14	2021-07-28	Janssen Pharmaceutica Nv	A menin-MLL kölcsönhatás spiro-biciklusos inhibitorai
MA46341A (fr)	2016-10-03	2019-08-07	Janssen Pharmaceutica Nv	Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
WO2018065365A1 (en)	2016-10-03	2018-04-12	Janssen Pharmaceutica Nv	Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
AU2017376599B2 (en)	2016-12-15	2021-10-07	Janssen Pharmaceutica Nv	Azepane inhibitors of menin-MLL interaction
GB201700526D0 (en) *	2017-01-12	2017-03-01	Univ Of Hull	Therapeutic use
MY195860A (en)	2017-02-27	2023-02-24	Janssen Pharmaceutica Nv	Use of Biomarkers in Identifying Cancer Patients That will be Responsive to Treatment with a Prmt5 Inhibitor
EP3665179B1 (en)	2017-08-09	2021-06-09	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP7328218B2 (ja) *	2017-10-26	2023-08-16	プレリュードセラピューティクス，インコーポレイティド	タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
CN111741964A (zh) *	2017-12-05	2020-10-02	安杰斯制药公司	作为prmt5抑制剂的杂环化合物
BR112020010815A2 (pt)	2017-12-08	2020-11-10	Janssen Pharmaceutica Nv	análogos espirobicíclicos
CU24621B1 (es) *	2017-12-13	2022-09-08	Lupin Ltd	Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
US11396517B1 (en)	2017-12-20	2022-07-26	Janssen Pharmaceutica Nv	Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en)	2018-03-14	2020-07-14	Prelude Therapeutics Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
DK3765461T3 (da) *	2018-03-14	2023-11-20	Prelude Therapeutics Inc	Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere
WO2020033285A1 (en) *	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
BR112021002267A8 (pt) *	2018-08-07	2023-02-07	Merck Sharp & Dohme	Inibidores de prmt5
WO2020033282A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2020033284A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
US12435088B2 (en)	2018-12-21	2025-10-07	Memorial Sloan-Kettering Cancer Center	Salicyl-adenosinemonosulfamate analogs and uses thereof
CN109400545B (zh) *	2018-12-24	2022-03-25	济南大学	一种精氨酸甲基转移酶5抑制剂及其应用
CN109369507A (zh) *	2018-12-26	2019-02-22	重庆市碚圣医药科技股份有限公司	一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法
US20220160713A1 (en) *	2019-02-13	2022-05-26	Prelude Therapeutics, Incorporated	Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
EP3939988A4 (en) *	2019-03-20	2022-08-24	Korea Research Institute of Chemical Technology	Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient
CA3134779A1 (en) *	2019-03-25	2020-10-01	California Institute Of Technology	Prmt5 inhibitors and uses thereof
AU2020256166A1 (en)	2019-04-02	2021-10-14	Aligos Therapeutics, Inc.	Compounds targeting PRMT5
WO2020206289A1 (en) *	2019-04-05	2020-10-08	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5
WO2020206299A1 (en)	2019-04-05	2020-10-08	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5
JP2022534998A (ja) *	2019-05-30	2022-08-04	エンジェクスファーマシューティカルインコーポレイテッド	Ｐｒｍｔ５阻害剤としての複素環式化合物
TW202112375A (zh)	2019-06-06	2021-04-01	比利時商健生藥品公司	使用ｐｒｍｔ５抑制劑治療癌症之方法
CR20220010A (es) *	2019-06-10	2022-05-13	Lupin Ltd	Inhibidores de prmt5
CR20220012A (es) *	2019-06-12	2022-03-11	Janssen Pharmaceutica Nv	Nuevos intermedios espirobiciclicos
US12414953B2 (en) *	2019-09-18	2025-09-16	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
AU2020372002A1 (en) *	2019-10-21	2022-05-26	Accent Therapeutics, Inc	Mettl3 modulators
MX2022004917A (es)	2019-10-22	2022-08-04	Lupin Ltd	Combinación farmacéutica de inhibidores de prmt5.
GB201915447D0 (en) *	2019-10-24	2019-12-11	Johnson Matthey Plc	Polymorphs of avapritinib and methods of preparing the polymorphs
US20230066014A1 (en) *	2019-12-03	2023-03-02	Lupin Limited	Substituted nucleoside analogs as prmt5 inhibitors
EP4076460B1 (en)	2019-12-17	2026-01-21	Merck Sharp & Dohme LLC	1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
UY38988A (es)	2019-12-19	2021-06-30	Janssen Pharmaceutica Nv	Derivados espiráncos sustituidos de cadena lineal
TWI883391B (zh)	2020-02-18	2025-05-11	美商基利科學股份有限公司	抗病毒化合物
CN118598916A (zh)	2020-02-18	2024-09-06	吉利德科学公司	抗病毒化合物
TWI775313B (zh)	2020-02-18	2022-08-21	美商基利科學股份有限公司	抗病毒化合物
CN111233869B (zh) *	2020-03-12	2022-09-16	杭州新博思生物医药有限公司	用于制备瑞德西韦关键中间体的新化合物及其制备方法
US20220112194A1 (en) *	2020-04-01	2022-04-14	Aligos Therapeutics, Inc.	Compounds targeting prmt5
US20240101589A1 (en) *	2020-10-08	2024-03-28	Strom Therapeutics Limited	Inhibitors of mettl3
CN112645875A (zh) *	2020-12-09	2021-04-13	深圳海王医药科技研究院有限公司	一种盐酸丙卡特罗杂质的制备方法
CN117120444A (zh)	2021-04-16	2023-11-24	吉利德科学公司	使用酰胺制备卡巴核苷的方法
CN113234079B (zh) *	2021-04-30	2022-02-01	上海湃隆生物科技有限公司	用作prmt5抑制剂的核苷类似物
WO2023001133A1 (zh) *	2021-07-20	2023-01-26	上海齐鲁制药研究中心有限公司	Prmt5抑制剂
CN115703796A (zh) *	2021-08-09	2023-02-17	苏州恩泰新材料科技有限公司	一种瑞德西韦重要中间体制备方法
JP7719954B2 (ja)	2021-08-18	2025-08-06	ギリアードサイエンシーズ，インコーポレイテッド	リン脂質化合物並びにその製造方法及び使用方法
GB202117230D0 (en)	2021-11-29	2022-01-12	Argonaut Therapeutics Ltd	Peptide vaccine
GB202203588D0 (en)	2022-03-15	2022-04-27	Argonaut Therapeutics Ltd	Cancer diagnostic
CN116655638B (zh) *	2022-05-12	2024-01-26	上海齐鲁制药研究中心有限公司	氘代prmt5抑制剂
CN116003339B (zh) *	2022-12-01	2024-06-28	南京师范大学	一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用
WO2024170488A1 (en)	2023-02-13	2024-08-22	Astrazeneca Ab	Prmt5 inhibitor for use in cancer therapy
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en)	2023-10-12	2025-04-17	Revolution Medicines, Inc.	Ras inhibitors
EP4553080A1 (en)	2023-11-07	2025-05-14	Ustav Organicke Chemie a Biochemie AV CR, v.v.i.	Nucleoside derivatives as antiviral agents against coronaviruses
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026008533A1 (en)	2024-07-01	2026-01-08	Janssen Pharmaceutica Nv	Prmt5 inhibitors for treating adenomas
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4224438A (en)	1970-07-14	1980-09-23	Boehringer Mannheim Gmbh	Adenosine-5'-carboxylic acid amides
US6143749A (en)	1995-06-07	2000-11-07	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
AU2002351077A1 (en)	2001-11-05	2003-05-19	Exiqon A/S	Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en)	2001-11-29	2006-04-25	Irm Llc	Nucleoside analog libraries
EP2412716A1 (en) *	2002-02-19	2012-02-01	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
US20040043959A1 (en) *	2002-03-04	2004-03-04	Bloom Laura A.	Combination therapies for treating methylthioadenosine phosphorylase deficient cells
KR100944140B1 (ko) *	2002-03-20	2010-02-24	스미또모 가가꾸 가부시끼가이샤	포지티브형 레지스트 조성물
AU2002951247A0 (en)	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
WO2005005450A1 (ja)	2003-07-15	2005-01-20	Mitsui Chemicals, Inc.	環状ビスジヌクレオシドの合成方法
AU2004311702A1 (en)	2003-12-19	2005-07-21	Koronis Pharmaceuticals, Inc.	Mutagenic heterocycles
EP1844062A2 (en)	2005-01-21	2007-10-17	Methylgene, Inc.	Inhibitors of dna methyltransferase
JP2009542608A (ja)	2006-06-29	2009-12-03	アステックス・セラピューティクス・リミテッド	医薬組合せ剤
US20080132525A1 (en)	2006-12-04	2008-06-05	Methylgene Inc.	Inhibitors of DNA Methyltransferase
US8962580B2 (en)	2008-09-23	2015-02-24	Alnylam Pharmaceuticals, Inc.	Chemical modifications of monomers and oligonucleotides with cycloaddition
BR112012014925A2 (pt)	2009-12-18	2017-03-01	Joslin Diabetes Center Inc	compostos promotores de replicação de células beta e métodos de uso dos mesmos
RU2013130253A (ru) *	2010-12-03	2015-01-10	Эпизайм, Инк.	7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения
AU2011341441A1 (en)	2010-12-03	2013-06-20	Epizyme, Inc.	Modulators of histone methyltransferase, and methods of use thereof
CA2819894A1 (en)	2010-12-16	2012-06-21	Abbvie Inc.	Anti-viral compounds
US9284343B2 (en)	2011-04-04	2016-03-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
EP2771012A4 (en)	2011-10-24	2015-06-24	Glaxosmithkline Ip No 2 Ltd	NEW CONNECTIONS
US20150057243A1 (en)	2012-04-02	2015-02-26	Northern University	Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (en) *	2012-08-30	2014-03-06	Kainos Medicine, Inc.	Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en)	2012-08-31	2014-04-10	Baylor College Of Medicine	Selective inhibitors of histone methyltransferase dot1l
WO2014100716A1 (en)	2012-12-21	2014-06-26	Epizyme, Inc.	Prmt5 inhibitors and uses thereof
HRP20182037T1 (hr) *	2012-12-21	2019-02-08	Epizyme, Inc.	Inhibitori prmt5 i njihova uporaba
US9745291B2 (en)	2012-12-21	2017-08-29	Epizyme, Inc.	PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US8906900B2 (en)	2012-12-21	2014-12-09	Epizyme, Inc.	PRMT5 inhibitors and uses thereof
EP2975938A4 (en)	2013-03-15	2017-02-15	Ohio State Innovation Foundation	Inhibitors of prmt5 and methods of their use
US10087151B2 (en)	2014-01-09	2018-10-02	The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone	Substituted benzoxazine and related compounds
EP3160477A4 (en)	2014-06-25	2018-07-04	Epizyme, Inc.	Prmt5 inhibitors and uses thereof
TN2016000581A1 (en)	2014-07-01	2018-04-04	Millennium Pharm Inc	Heteroaryl compounds useful as inhibitors of sumo activating enzyme
EP3262057B1 (en)	2015-02-24	2020-04-15	Pfizer Inc	Substituted nucleoside derivatives useful as anticancer agents
TWI791251B (zh) *	2015-08-26	2023-02-01	比利時商健生藥品公司	使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
KR20180116307A (ko)	2016-03-10	2018-10-24	얀센 파마슈티카 엔.브이.	Prmt5 저해제로 사용하기 위한 치환 뉴클레오사이드 유사체
MA46341A (fr) *	2016-10-03	2019-08-07	Janssen Pharmaceutica Nv	Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
WO2018065365A1 (en)	2016-10-03	2018-04-12	Janssen Pharmaceutica Nv	Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MY195860A (en)	2017-02-27	2023-02-24	Janssen Pharmaceutica Nv	Use of Biomarkers in Identifying Cancer Patients That will be Responsive to Treatment with a Prmt5 Inhibitor
BR112020010815A2 (pt)	2017-12-08	2020-11-10	Janssen Pharmaceutica Nv	análogos espirobicíclicos

2016
- 2016-08-24 TW TW110127686A patent/TWI791251B/zh active
- 2016-08-24 TW TW112102610A patent/TWI870767B/zh active
- 2016-08-24 TW TW105126988A patent/TWI730980B/zh active
- 2016-08-25 TN TNP/2018/000043A patent/TN2018000043A1/en unknown
- 2016-08-25 US US15/755,475 patent/US10653711B2/en active Active
- 2016-08-25 EP EP21199207.8A patent/EP3974428A1/en active Pending
- 2016-08-25 PT PT167572338T patent/PT3341368T/pt unknown
- 2016-08-25 BR BR112018003595-5A patent/BR112018003595B1/pt active IP Right Grant
- 2016-08-25 EP EP16757233.8A patent/EP3341368B1/en active Active
- 2016-08-25 SI SI201631402T patent/SI3341368T1/sl unknown
- 2016-08-25 PH PH1/2018/500425A patent/PH12018500425B1/en unknown
- 2016-08-25 MY MYPI2018000274A patent/MY198472A/en unknown
- 2016-08-25 PE PE2022000450A patent/PE20221629A1/es unknown
- 2016-08-25 CN CN201680048987.1A patent/CN107922413B/zh active Active
- 2016-08-25 PL PL16757233T patent/PL3341368T3/pl unknown
- 2016-08-25 LT LTEPPCT/EP2016/070097T patent/LT3341368T/lt unknown
- 2016-08-25 CN CN202111120182.2A patent/CN114057815B/zh active Active
- 2016-08-25 NZ NZ740528A patent/NZ740528A/en unknown
- 2016-08-25 WO PCT/EP2016/070097 patent/WO2017032840A1/en not_active Ceased
- 2016-08-25 HR HRP20211997TT patent/HRP20211997T1/hr unknown
- 2016-08-25 RS RS20211526A patent/RS62698B1/sr unknown
- 2016-08-25 EA EA201890573A patent/EA201890573A1/ru unknown
- 2016-08-25 KR KR1020187007810A patent/KR102716092B1/ko active Active
- 2016-08-25 ES ES16757233T patent/ES2901972T3/es active Active
- 2016-08-25 BR BR122023020317-8A patent/BR122023020317A2/pt not_active Application Discontinuation
- 2016-08-25 AR ARP160102600A patent/AR105820A1/es active IP Right Grant
- 2016-08-25 HU HUE16757233A patent/HUE057312T2/hu unknown
- 2016-08-25 SM SM20210725T patent/SMT202100725T1/it unknown
- 2016-08-25 MD MDE20180642T patent/MD3341368T2/ro unknown
- 2016-08-25 IL IL311843A patent/IL311843A/en unknown
- 2016-08-25 AU AU2016311295A patent/AU2016311295B2/en active Active
- 2016-08-25 NZ NZ779003A patent/NZ779003A/en unknown
- 2016-08-25 EP EP23162887.6A patent/EP4219496A1/en active Pending
- 2016-08-25 JP JP2018510334A patent/JP6917978B2/ja active Active
- 2016-08-25 DK DK16757233.8T patent/DK3341368T3/da active
- 2016-08-25 MX MX2018002326A patent/MX392554B/es unknown
- 2016-08-25 SG SG10202003775VA patent/SG10202003775VA/en unknown
- 2016-08-25 MA MA42678A patent/MA42678B1/fr unknown
- 2016-08-25 PH PH1/2021/552054A patent/PH12021552054A1/en unknown
- 2016-08-25 PE PE2018000306A patent/PE20180929A1/es unknown
- 2016-08-25 CA CA2992688A patent/CA2992688A1/en active Pending
2018
- 2018-02-21 IL IL257664A patent/IL257664B/en active IP Right Grant
- 2018-02-23 MX MX2022005182A patent/MX2022005182A/es unknown
- 2018-02-26 CO CONC2018/0002063A patent/CO2018002063A2/es unknown
- 2018-02-26 CL CL2018000510A patent/CL2018000510A1/es unknown
2020
- 2020-03-20 US US16/825,024 patent/US11318157B2/en active Active
2021
- 2021-01-20 AU AU2021200345A patent/AU2021200345B2/en active Active
- 2021-04-21 IL IL282537A patent/IL282537A/en unknown
- 2021-07-20 JP JP2021120042A patent/JP7720732B2/ja active Active
2022
- 2022-01-04 CY CY20221100008T patent/CY1125359T1/el unknown
- 2022-03-09 US US17/690,587 patent/US11883367B2/en active Active
- 2022-08-11 AU AU2022215260A patent/AU2022215260B2/en active Active
2023
- 2023-03-21 US US18/187,463 patent/US20230330127A1/en not_active Abandoned
- 2023-10-27 JP JP2023184701A patent/JP2024012405A/ja not_active Withdrawn
2024
- 2024-03-28 AU AU2024202052A patent/AU2024202052A1/en active Pending

Also Published As

Publication number	Publication date
LT3341368T (lt)	2021-12-10
AU2021200345A1 (en)	2021-03-18
US11318157B2 (en)	2022-05-03
BR122023020317A2 (pt)	2023-12-12
PE20180929A1 (es)	2018-06-08
KR20180041222A (ko)	2018-04-23
PL3341368T3 (pl)	2022-02-14
JP2021169520A (ja)	2021-10-28
PH12021552054A1 (en)	2022-05-02
AU2022215260A1 (en)	2022-09-01
AR105820A1 (es)	2017-11-15
MA42678B1 (fr)	2021-11-30
AU2016311295B2 (en)	2020-10-22
TW201718575A (zh)	2017-06-01
PH12018500425A1 (en)	2018-09-10
WO2017032840A1 (en)	2017-03-02
AU2022215260B2 (en)	2024-04-18
CN107922413A (zh)	2018-04-17
CA2992688A1 (en)	2017-03-02
HK1253898A1 (zh)	2019-07-05
IL282537A (en)	2021-06-30
EP4219496A1 (en)	2023-08-02
NZ740528A (en)	2024-11-29
CN114057815B (zh)	2025-02-25
MX392554B (es)	2025-03-24
MY198472A (en)	2023-08-31
AU2021200345B2 (en)	2022-08-04
SI3341368T1 (sl)	2022-01-31
EP3341368B1 (en)	2021-10-06
US20200360416A1 (en)	2020-11-19
BR112018003595A2 (pt)	2018-09-25
PH12018500425B1 (en)	2022-09-02
US11883367B2 (en)	2024-01-30
JP2024012405A (ja)	2024-01-30
HUE057312T2 (hu)	2022-05-28
NZ779003A (en)	2024-12-20
IL257664A (en)	2018-04-30
MX2022005182A (es)	2022-05-16
EP3974428A1 (en)	2022-03-30
MD3341368T2 (ro)	2022-02-28
MA42678A (fr)	2021-05-19
US20230071711A1 (en)	2023-03-09
CN114057815A (zh)	2022-02-18
TW202146414A (zh)	2021-12-16
JP7720732B2 (ja)	2025-08-08
SMT202100725T1 (it)	2022-01-10
MX2018002326A (es)	2018-04-11
IL311843A (en)	2024-05-01
AU2024202052A1 (en)	2024-04-18
HK1257099A1 (en)	2019-10-11
DK3341368T3 (da)	2021-12-20
RS62698B1 (sr)	2022-01-31
PE20221629A1 (es)	2022-10-19
EP3341368A1 (en)	2018-07-04
SG10202003775VA (en)	2020-06-29
CN107922413B (zh)	2021-10-01
CL2018000510A1 (es)	2018-07-06
HRP20211997T1 (hr)	2022-04-01
JP2018528946A (ja)	2018-10-04
KR102716092B1 (ko)	2024-10-10
US20180243328A1 (en)	2018-08-30
TWI730980B (zh)	2021-06-21
US10653711B2 (en)	2020-05-19
CO2018002063A2 (es)	2018-07-19
TN2018000043A1 (en)	2019-07-08
TW202321249A (zh)	2023-06-01
AU2016311295A1 (en)	2018-02-08
CY1125359T1 (el)	2024-02-16
BR112018003595B1 (pt)	2024-03-12
JP6917978B2 (ja)	2021-08-11
TWI791251B (zh)	2023-02-01
TWI870767B (zh)	2025-01-21
ES2901972T3 (es)	2022-03-24
EA201890573A1 (ru)	2018-07-31
US20230330127A1 (en)	2023-10-19
IL257664B (en)	2021-05-31

Publication	Publication Date	Title
IL282537A (en)	2021-06-30	Novel 6–6 bicyclic aromatic ring-converted nucleoside analogs for use as PRMT5 inhibitors
IL261559A (en)	2018-10-31	Nucleoside analogues are converted for use as prmt5 inhibitors
IL288519B1 (en)	2023-05-01	inhibitors of ret
IL286428A (en)	2021-10-31	Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases
ZA201800480B (en)	2018-11-28	New bicyclic compounds as dual atx/ca inhibitors
ZA201801032B (en)	2018-12-19	Bicyclic compounds as atx inhibitors
ZA202003528B (en)	2022-05-25	Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
IL255570A (en)	2018-01-31	Bicyclic compounds as atx inhibitors
IL255511B (en)	2020-01-30	New bicyclic compounds as dual atx/ca inhibitors
EP3212657A4 (en)	2018-04-11	Methods of preparing substituted nucleoside analogs
IL249456A0 (en)	2017-02-28	Methods for preparing analogues of modified nucleotides
IL265718B (en)	2021-08-31	Novel modified carbonucleoside analogs with monocyclic and cyclic ring systems as prmt5 inhibitors
HUE053463T2 (hu)	2021-06-28	Pirrolopirimidin vegyületek, amelyek használhatók JAK inhibitorokként
IL253848A0 (en)	2017-09-28	Amine compounds as 5-hydroxytryptamine 4 receptor agonists
IL255357A0 (en)	2017-12-31	bicyclic compounds
IL256226A (en)	2018-02-28	Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
ZA201806016B (en)	2022-04-28	Substituted nucleoside analogues for use as prmt5 inhibitors